Advanced search
Publication Cover
Journal of Medical Economics Volume 21, 2018 - Issue 10
Submit an article Journal homepage
1,841
Views
7
CrossRef citations to date
0
Altmetric
Neurology

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands

M. A. PienaPharmerit International, Rotterdam, The Netherlands; Correspondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6707-6796
ORCID Icon,
M. HeisenPharmerit International, Rotterdam, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-5339-6606
ORCID Icon,
L. W. WormhoudtSanofi Genzyme Netherlands, Naarden, The Netherlands;
,
J. van WingerdenSanofi Genzyme Netherlands, Naarden, The Netherlands;
,
S. T. F. M. FrequinDepartment of Neurology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands;
&
B. M. J. UitdehaagDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands
Pages 968-976 | Received 11 Apr 2018, Accepted 10 Jun 2018, Published online: 09 Jul 2018

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Emanuele D’Amico, Clara G Chisari, Lara Gitto, Aurora Zanghì, Simona Toscano & Francesco Patti. (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy 20:11, pages 1331-1340.
Read now

Articles from other publishers (6)

Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador & Julio Dotor García-Soto. (2023) Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. Frontiers in Neurology 14.
Crossref
Y. Seitaridou, M. Dimitrova, T. Chamova, M. Kamusheva & P. Panayotov. (2022) Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review. Acta Medica Bulgarica 49:4, pages 69-80.
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
S. Simeonova & R. Nikolova. (2021) Significance of the Dominant Psychological and Physiological Aspects of the Occupational Stress Models. Acta Medica Bulgarica 48:4, pages 33-42.
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Laura Foucault-Fruchard, Hervé Watier & Daniel Antier. (2020) Dénominations et indications des anticorps face à la réglementation et aux pratiques des laboratoires pharmaceutiques. médecine/sciences 35:12, pages 1189-1193.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.